Analysis Tools
mortality/aging
|
• mice develop a wasting syndrome and succumb to disease by 11 weeks of age
|
growth/size/body
|
• mice develop an enlarged spleen
|
integument
|
• loss of hypodermal fat
|
|
• marker analysis indicates impaired keratinocyte differentiation
|
|
• mice with advanced disease show loss of skin barrier integrity at 7-8 weeks of age
|
dermatitis
(
J:226194
)
|
• mice develop severe, systemic dermatitis starting at 5 weeks of age
• inflammation is not seen in the lung, liver, kidney or gut
|
|
• dermatitis is accompanied by hair loss
|
|
• loss of hair follicles
|
|
• mild epidermal hyperplasia and microabsceess are seen at 3 weeks of age but not at 10 days of age
|
scaly skin
(
J:226194
)
|
• skin contains epidermal scales
|
skin lesions
(
J:226194
)
|
• skin of mice with advanced disease contains lesions with epidermal damage, resulting in loss of skin barrier integrity
|
thick skin
(
J:226194
)
|
• dermatitis is accompanied by skin thickening
|
|
• increase in dermal fibrosis
|
immune system
|
• mice develop an enlarged spleen
|
|
• decrease in the frequency of Foxp3+ CD25+ Tregs with a corresponding increase in Foxp3-CD25+ effector T cells
|
|
• CD4 T cells exhibit an activated phenotype
• mice develop systemic T helper type 2 immunity
|
|
• mice develop peripheral lymphadenopathy
|
dermatitis
(
J:226194
)
|
• mice develop severe, systemic dermatitis starting at 5 weeks of age
• inflammation is not seen in the lung, liver, kidney or gut
|
homeostasis/metabolism
|
• mice with advanced disease show loss of skin barrier integrity at 7-8 weeks of age
|
hematopoietic system
|
• mice develop an enlarged spleen
|
|
• decrease in the frequency of Foxp3+ CD25+ Tregs with a corresponding increase in Foxp3-CD25+ effector T cells
|
|
• CD4 T cells exhibit an activated phenotype
• mice develop systemic T helper type 2 immunity
|
cellular
|
• marker analysis indicates impaired keratinocyte differentiation
|
adipose tissue
|
• loss of hypodermal fat
|
